In myelodysplastic syndromes, thrombocytopenia is associated with mortality, but treatments in this setting are scarce. We tested whether eltrombopag, a thrombopoietin receptor agonist, might be effective in improving thrombocytopenia in lower-risk myelodysplastic syndromes and severe thrombocytopenia.

Oliva, E., Alati, C., Santini, V., Poloni, A., Molteni, A., Niscola, P., et al. (2017). Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): Phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial. THE LANCET. HAEMATOLOGY, 4(3), e127-e136 [10.1016/S2352-3026(17)30012-1].

Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): Phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial

BUCCISANO, FRANCESCO;VOSO, MARIA TERESA;
2017

Abstract

In myelodysplastic syndromes, thrombocytopenia is associated with mortality, but treatments in this setting are scarce. We tested whether eltrombopag, a thrombopoietin receptor agonist, might be effective in improving thrombocytopenia in lower-risk myelodysplastic syndromes and severe thrombocytopenia.
In corso di stampa
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/15 - Malattie del Sangue
English
Oliva, E., Alati, C., Santini, V., Poloni, A., Molteni, A., Niscola, P., et al. (2017). Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): Phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial. THE LANCET. HAEMATOLOGY, 4(3), e127-e136 [10.1016/S2352-3026(17)30012-1].
Oliva, E; Alati, C; Santini, V; Poloni, A; Molteni, A; Niscola, P; Salvi, F; Sanpaolo, G; Balleari, E; Germing, U; Fenaux, P; Stamatoullas, A; Palumbo, G; Salutari, P; Impera, S; Avanzini, P; Cortelezzi, A; Liberati, A; Carluccio, P; Buccisano, F; Voso, Mt; Mancini, S; Kulasekararaj, A; Morabito, F; Bocchia, M; Cufari, P; Spiriti, M; Santacaterina, I; D'Errigo, M; Bova, I; Zini, G; Latagliata, R
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
oliva2017.pdf

non disponibili

Tipologia: Versione Editoriale (PDF)
Licenza: Copyright dell'editore
Dimensione 848.92 kB
Formato Adobe PDF
848.92 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2108/173312
Citazioni
  • ???jsp.display-item.citation.pmc??? 30
  • Scopus 98
  • ???jsp.display-item.citation.isi??? 90
social impact